• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5071034)   Today's Articles (71)
For: Kuo AMS, Gu S, Stoll J, Moy AP, Dusza SW, Gordon A, Haliasos EC, Janjigian Y, Kraehenbuehl L, Quigley EA, Chapman P, Lacouture ME, Markova A. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer 2023;11:e007324. [PMID: 37270183 PMCID: PMC10255229 DOI: 10.1136/jitc-2023-007324] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/21/2023] [Indexed: 06/05/2023]  Open
Number Cited by Other Article(s)
1
Ghamangiz S, Jafari A, Maleki-Kakelar H, Azimi H, Mazloomi E. Reprogram to heal: Macrophage phenotypes as living therapeutics. Life Sci 2025;371:123601. [PMID: 40189197 DOI: 10.1016/j.lfs.2025.123601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Revised: 03/15/2025] [Accepted: 04/01/2025] [Indexed: 04/26/2025]
2
Lavin L, Geller S. Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations. Am J Clin Dermatol 2025:10.1007/s40257-025-00955-7. [PMID: 40418285 DOI: 10.1007/s40257-025-00955-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2025] [Indexed: 05/27/2025]
3
Koumprentziotis IA, Niforou A, Tsimpidakis A, Nikolaou C, Stratigos A, Nikolaou V. Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review. Int J Dermatol 2025. [PMID: 40375468 DOI: 10.1111/ijd.17850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2025] [Revised: 04/30/2025] [Accepted: 05/06/2025] [Indexed: 05/18/2025]
4
Khattab S, Wan G, Xu S, Moseley C, Tran M, Beagles E, Lin C, Leung BW, Azin M, Hao N, Reynolds KL, Demehri S, LeBoeuf NR, Semenov YR. Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events. J Immunother Cancer 2025;13:e010638. [PMID: 40355282 PMCID: PMC12083386 DOI: 10.1136/jitc-2024-010638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2024] [Accepted: 04/23/2025] [Indexed: 05/14/2025]  Open
5
Gillis MC, Weir VR, Lezcano C, Iyer G, Gordon A. Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma. JAAD Case Rep 2025;56:40-44. [PMID: 39839459 PMCID: PMC11750431 DOI: 10.1016/j.jdcr.2024.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2025]  Open
6
Lauletta G, Potestio L, Patruno C, De Lucia M, Napolitano M. Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review. Clin Cosmet Investig Dermatol 2025;18:311-317. [PMID: 39901963 PMCID: PMC11789671 DOI: 10.2147/ccid.s511559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2024] [Accepted: 01/26/2025] [Indexed: 02/05/2025]
7
Zhang X, Zhang B, Li D, Yang Y, Lin S, Zhao R, Li Y, Peng L. Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol 2025;16:1528084. [PMID: 39949762 PMCID: PMC11821924 DOI: 10.3389/fimmu.2025.1528084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2024] [Accepted: 01/13/2025] [Indexed: 02/16/2025]  Open
8
Chowdhury D, Chin L, Odabashian R, Fawaz A, Canil C, Ong M, Kirchhof MG, Reaume MN, Beltran-Bless AA, Savard MF, Tsoulis DJ, Bossé D. Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers. Cancers (Basel) 2025;17:251. [PMID: 39858032 PMCID: PMC11763385 DOI: 10.3390/cancers17020251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2024] [Revised: 01/05/2025] [Accepted: 01/09/2025] [Indexed: 01/27/2025]  Open
9
Khattab S, Wan G, Xu S, Moseley C, Tran M, Beagles E, Lin C, Leung B, Azin M, Hao N, Reynolds KL, Demehri S, LeBoeuf NR, Semenov YR. Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2025:2025.01.07.25320156. [PMID: 39830283 PMCID: PMC11741467 DOI: 10.1101/2025.01.07.25320156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2025]
10
Justice J, Kankaria RA, Johnson DB. Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity. Expert Rev Clin Pharmacol 2024;17:1115-1125. [PMID: 39570086 DOI: 10.1080/17512433.2024.2431513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2024] [Accepted: 11/15/2024] [Indexed: 11/22/2024]
11
Jiménez-Andrade Y, Flesher JL, Park JM. Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity. Hematol Oncol Clin North Am 2024;38:1011-1025. [PMID: 38866636 PMCID: PMC11368641 DOI: 10.1016/j.hoc.2024.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2024]
12
Mima Y, Ohtsuka T, Ebato I, Nakata Y, Tsujita A, Nakazato Y, Norimatsu Y. Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment. Biomedicines 2024;12:1886. [PMID: 39200350 PMCID: PMC11352049 DOI: 10.3390/biomedicines12081886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2024] [Revised: 08/14/2024] [Accepted: 08/15/2024] [Indexed: 09/02/2024]  Open
13
Pach J, Valido K, Belzer A, Leventhal JS. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases. Am J Clin Dermatol 2024;25:595-607. [PMID: 38767827 DOI: 10.1007/s40257-024-00866-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/22/2024] [Indexed: 05/22/2024]
14
Metko D, Alkofide M, Abu-Hilal M. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities. JAAD Int 2024;15:5-11. [PMID: 38371662 PMCID: PMC10869314 DOI: 10.1016/j.jdin.2024.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/09/2024] [Indexed: 02/20/2024]  Open
15
McClatchy J, Ross G. Dupilumab for atopic dermatitis in metastatic cancer. Australas J Dermatol 2024. [PMID: 38699896 DOI: 10.1111/ajd.14296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 04/04/2024] [Accepted: 04/14/2024] [Indexed: 05/05/2024]
16
Saeed HN, Micheletti R, Phillips EJ. Editorial: Stevens Johnson syndrome: past, present, and future directions. Front Med (Lausanne) 2024;11:1383891. [PMID: 38515984 PMCID: PMC10955758 DOI: 10.3389/fmed.2024.1383891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Accepted: 02/26/2024] [Indexed: 03/23/2024]  Open
17
Gu SL, Nath S, Markova A. Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events. Pharmaceuticals (Basel) 2023;16:1610. [PMID: 38004475 PMCID: PMC10674388 DOI: 10.3390/ph16111610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 11/08/2023] [Accepted: 11/11/2023] [Indexed: 11/26/2023]  Open
18
Kraehenbuehl L, Schneider S, Pawlik L, Mangana J, Cheng P, Dummer R, Meier-Schiesser B. Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis. Pharmaceuticals (Basel) 2023;16:935. [PMID: 37513847 PMCID: PMC10383648 DOI: 10.3390/ph16070935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 05/28/2023] [Accepted: 06/22/2023] [Indexed: 07/30/2023]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA